» Articles » PMID: 35972133

Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model

Overview
Journal mSphere
Date 2022 Aug 16
PMID 35972133
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic (long-lasting) infections are globally a major and rising cause of morbidity and mortality. Unlike typical acute infections, chronic infections are ecologically diverse, characterized by the presence of a polymicrobial mix of opportunistic pathogens and human-associated commensals. To address the challenge of chronic infection microbiomes, we focus on a particularly well-characterized disease, cystic fibrosis (CF), where polymicrobial lung infections persist for decades despite frequent exposure to antibiotics. Epidemiological analyses point to conflicting results on the benefits of antibiotic treatment yet are confounded by the dependency of antibiotic exposures on prior pathogen presence, limiting their ability to draw causal inferences on the relationships between antibiotic exposure and pathogen dynamics. To address this limitation, we develop a synthetic infection microbiome model representing CF metacommunity diversity and benchmark on clinical data. We show that in the absence of antibiotics, replicate microbiome structures in a synthetic sputum medium are highly repeatable and dominated by oral commensals. In contrast, challenge with physiologically relevant antibiotic doses leads to substantial community perturbation characterized by multiple alternate pathogen-dominant states and enrichment of drug-resistant species. These results provide evidence that antibiotics can drive the expansion (via competitive release) of previously rare opportunistic pathogens and offer a path toward microbiome-informed conditional treatment strategies. We develop and clinically benchmark an experimental model of the cystic fibrosis (CF) lung infection microbiome to investigate the impacts of antibiotic exposures on chronic, polymicrobial infections. We show that a single experimental model defined by metacommunity data can partially recapitulate the diversity of individual microbiome states observed across a population of people with CF. In the absence of antibiotics, we see highly repeatable community structures, dominated by oral microbes. Under clinically relevant antibiotic exposures, we see diverse and frequently pathogen-dominated communities, and a nonevolutionary enrichment of antimicrobial resistance on the community scale, mediated by competitive release. The results highlight the potential importance of nonevolutionary (community-ecological) processes in driving the growing global crisis of increasing antibiotic resistance.

Citing Articles

An eco-evolutionary perspective on antimicrobial resistance in the context of One Health.

Bustamante M, Mei S, Daras I, van Doorn G, Falcao Salles J, de Vos M iScience. 2025; 28(1):111534.

PMID: 39801834 PMC: 11719859. DOI: 10.1016/j.isci.2024.111534.


A cross-systems primer for synthetic microbial communities.

Mehlferber E, Arnault G, Joshi B, Partida-Martinez L, Patras K, Simonin M Nat Microbiol. 2024; 9(11):2765-2773.

PMID: 39478083 PMC: 11660114. DOI: 10.1038/s41564-024-01827-2.


Host tracheal and intestinal microbiomes inhibit growth .

Tejeda-Garibay S, Zhao L, Hum N, Pimentel M, Diep A, Amiri B Microbiol Spectr. 2024; 12(7):e0297823.

PMID: 38832766 PMC: 11218535. DOI: 10.1128/spectrum.02978-23.


The impact of phage and phage resistance on microbial community dynamics.

Alseth E, Custodio R, Sundius S, Kuske R, Brown S, Westra E PLoS Biol. 2024; 22(4):e3002346.

PMID: 38648198 PMC: 11034675. DOI: 10.1371/journal.pbio.3002346.


Disentangling direct vs indirect effects of microbiome manipulations in a habitat-forming marine holobiont.

McGrath A, Lema K, Egan S, Wood G, Vadillo Gonzalez S, Kjelleberg S NPJ Biofilms Microbiomes. 2024; 10(1):33.

PMID: 38553475 PMC: 10980776. DOI: 10.1038/s41522-024-00503-x.


References
1.
Holden M, Seth-Smith H, Crossman L, Sebaihia M, Bentley S, Cerdeno-Tarraga A . The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol. 2008; 191(1):261-77. PMC: 2612433. DOI: 10.1128/JB.01230-08. View

2.
Cipolla D, Blanchard J, Gonda I . Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics. 2016; 8(1). PMC: 4810082. DOI: 10.3390/pharmaceutics8010006. View

3.
Tunney M, Field T, Moriarty T, Patrick S, Doering G, Muhlebach M . Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 2008; 177(9):995-1001. DOI: 10.1164/rccm.200708-1151OC. View

4.
Wenzler E, Gotfried M, Loutit J, Durso S, Griffith D, Dudley M . Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. Antimicrob Agents Chemother. 2015; 59(12):7232-9. PMC: 4649232. DOI: 10.1128/AAC.01713-15. View

5.
Stacy A, McNally L, Darch S, Brown S, Whiteley M . The biogeography of polymicrobial infection. Nat Rev Microbiol. 2015; 14(2):93-105. PMC: 5116812. DOI: 10.1038/nrmicro.2015.8. View